Overview

InSightec developed ExAblate® 2000– a product that integrates focused ultrasound energy and Magnetic Resonance Imaging (MRI) to provide a non-invasive treatment modality that can replace invasive procedures and provide therapeutic alternatives. 

ExAblate was approved by the U.S. Food and Drug Administration (FDA) in October 2004 to treat symptomatic uterine fibroids and to date over 4500 women have been treated worldwide for symptomatic uterine fibroids. InSightec is conducting clinical trials in oncology indications: pain palliation of bone metastases, breast cancer, prostate , brain applications, liver tumors and Fertility Enhancement trial. 

ExAblate also received the European CE mark for treating pain palliation caused by bone metastatses.

History 

InSightec was founded in 1999 when GE Healthcare (then GE Medical Systems) and Elbit Medical Imaging transferred their proprietary technology to the company to enable it to concentrate on developing the promising MR guided focused ultrasound surgery both companies had investigated. Since then, InSightec has invested over $100 million in research and development. The company holds over 30 patents with additional intellectual property pending.

Team

The 160 InSightec staff includes world class scientists and engineers with extensive experience in the wide variety of disciplines involved with this enhanced technology and teamed with leading application specialists, manufacturing, service and other personnel. The company is headquartered in Tirat Carmel, Israel, near the port city of Haifa. Its US offices are in Dallas, Texas.

Clinical Partners

InSightec has established clinical collaborations with leading hospitals and medical research institutions around the world. Many of these sites participate in sponsored trials to gather clinical data that will advance the company’s technology and create an ever-widening spectrum of clinical applications. InSightec has over 65 sites globally.